Randomised clinical trials (23–25) of lung cancer patients with EGFR-sensitive mutation showed that first-line treatment with EGFR-TKIs achieved similar PFS benefits to chemotherapy in smokers and never-smokers. This evidence concerns the gene EGFR and lung cancer.